Nirsevimab Library
This is a collection of current resources related to Nirsevimab.
Update: Nirsevimab (Beyfortus) – FAQs for Healthcare Professionals
This update from the Pediatric Pandemic Network (PPN) describes the new guidelines from the CDC with additional recommendations from the FDA, AAP, and AAFP. There …
Ask aRCie
Respiratory Syncytial Virus and US Pediatric Intensive Care Utilization
2024
· Children's National Hospital
This study looks at how respiratory syncytial virus (RSV) affects children in the ICU. It describes that 11.4% of pediatric ICU admissions are due to …
Equitable Access to RSV Prevention: Challenges and Opportunities With Nirsevimab's Rollout
This editorial discusses challenges in achieving equal access to RSV prevention. This includes providing affordable vaccines, educating communities on prevention strategies, and implementing policies that …
Fall 2023 ACIP Update on Meningococcal, RSV, COVID-19, and Other Pediatric Vaccines
2024
· Children's National Hospital,
· University of South Florida,
· University of Alabama at Birmingham,
· University of Colorado,
· University of Cincinnati
This article summarizes updates from the Advisory Committee on Immunization Practices (ACIP), a group advising the CDC, relevant to pediatrics, including recommendations for COVID-19 and …
Assessment of Effectiveness and Impact of Universal Prophylaxis With Nirsevimab for Prevention of Hospitalizations Due to Respiratory Syncytial Virus in Infants. The NIRSE-GAL Study Protocol
2024
· Instituto de Investigación Sanitaria,
· World Health Organization (WHO),
· University of Santiago de Compostela,
· Instituto de Salud Carlos III
The NIRSE-GAL study in Galicia, Spain, aims to assess the effectiveness of nirsevimab in preventing hospitalizations due to Respiratory Syncytial Virus (RSV) in infants. It …
Cost-Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children
2024
· University of Michigan,
· Centers for Disease Control and Prevention (CDC),
· U.S. Public Health Service
This study evaluated the cost-effectiveness of using nirsevimab to prevent respiratory syncytial virus (RSV) in infants and high-risk children. By analyzing healthcare data, it was …
Infant Protection Against Respiratory Syncytial Virus (RSV) by Maternal RSV Vaccination or Receipt of Nirsevimab, and Intent for Nirsevimab Receipt, United States [Dataset]
This dataset provides monthly estimates of infant protection against RSV that were calculated using data from the National Immunization Survey–Adult COVID Module (NIS–ACM). The data …
Cost-Effectiveness of Maternal Vaccination to Prevent Respiratory Syncytial Virus Illness
2024
· University of Michigan,
· Centers for Disease Control and Prevention (CDC),
· U.S. Public Health Service
This study evaluates the benefits and cost-effectiveness of a vaccine for pregnant women to protect babies from RSV, a virus that can cause serious illness …
Notes from the Field: Rollout of Nirsevimab to Protect Infants and Young Children During the Respiratory Syncytial Virus Season — New York City, 2023–2024
2024
· New York City Department of Health and Mental Hygiene,
· Centers for Disease Control and Prevention (CDC)
This analysis reviewed nirsevimab dosing based on Vaccines for Children (VFC) eligibility in New York City during the 2023–24 RSV season. A nirsevimab shortage in …
Recommended Childhood and Adolescent Immunization Schedule: United States, 2024
This policy statement describes the 2024 recommended childhood and adolescent immunization schedules, approved by multiple medical organizations including the CDC and AAP. Updates include the …